The pharmacologic inhibition of PTP1B enhanced the response to PD-1 checkpoint blockade by repressing tumour development and decreasing T cell exhaustion, and it also promoted chimeric antigen receptor (CAR) T cell-mediated antitumour immunity, highlighting PTP1B inhibition as a promising target for cancer immunotherapy [34,35]. Here, PTPN1 is linked to neoplasm.